TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37393658
Drug: Adrenocorticotropic hormone
Normalized name: Adrenocorticotropic hormone
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adrenocorticotropic hormone (ACTH) stimulation
Study: 37393691
Drug: Interference testing
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interference testing of over-the-counter and common co-administered medications.
Study: 37393762
Drug: KN046 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: KN046 3 mg/kg
Study: 37393762
Drug: KN046 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: KN046 5 mg/kg
Study: 37394178
Drug: FMXIN002 3.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: FMXIN002 3.2 mg after nasal allergen challenge
Study: 37394627
Drug: Adavosertib (225
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adavosertib (225 mg bid) co-administration with cocktail
Study: 37394920
Drug: BMS-986141, a
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMS-986141, a novel, oral, PAR4 agonist, administered as a single ascending dose.
Study: 37395169
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment applied to each foot once a week for four weeks (n=16)
Study: 37395185
Drug: Activated recombinant
Normalized name: Activated Recombinant Human Factor VII, Long Acting
DrugBank: Eptacog alfa pegol (activated) (DB11661)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activated recombinant FVII (rFVIIa) at a recommended dose of 15-30 μg/kg
Study: 37395254
Drug: Integrase-strand transfer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrase-strand transfer inhibitors (INSTIs)
Study: 37395948
Drug: Ultrasound-guided dextrose
Normalized name: Dextrose
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided dextrose hydrodissection (1 mL of 50% dextrose, 4 mL of 1% lidocaine, and 5 mL of 1% normal saline)
Study: 37395974
Drug: Amlodipine, Losartan,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine, Losartan, Rosuvastatin, and Ezetimibe (A/L/R/E)
Study: 37395974
Drug: Amlodipine and
Normalized name: amlodipine and diuretics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine and Losartan (A/L)
Study: 37395974
Drug: Losartan, Rosuvastatin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan, Rosuvastatin, and Ezetimibe (L/R/E)
Study: 37396126
Drug: Innovative synbiotics
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Innovative synbiotics treatment for CKD patients
Study: 37397078
Drug: Remote Ischemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remote Ischemic Conditioning (RIC) - 3 cycles of 5-minute inflation of a blood pressure cuff to 15 mm Hg above systolic pressure before anthracycline therapy
Study: 37397433
Drug: Integrated pharmaceutical
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Integrated pharmaceutical care at psychosocial intervention
Study: 37397983
Drug: PPM-guided dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPM-guided dosing of tacrolimus
Study: 37397983
Drug: Standard-of-care (SOC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-of-care (SOC) clinician-determined dosing of tacrolimus
Study: 37398043
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of hrHPV testing followed by Gynocular
Study: 37398623
Drug: Elagolix 25
Normalized name: ELAGOLIX
DrugBank: Elagolix (DB11979)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Elagolix 25 mg twice daily
Study: 37398623
Drug: Elagolix 50
Normalized name: ELAGOLIX
DrugBank: Elagolix (DB11979)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Elagolix 50 mg once daily
Study: 37398623
Drug: Elagolix 75
Normalized name: ELAGOLIX
DrugBank: Elagolix (DB11979)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Elagolix 75 mg twice daily
Study: 37398623
Drug: Elagolix 300
Normalized name: elagolix 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elagolix 300 mg twice daily
Study: 37398623
Drug: Elagolix (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elagolix (all doses)
Study: 37398992
Drug: Ganitumab 18
Normalized name: Ganitumab
DrugBank: Ganitumab (DB12205)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ganitumab 18 mg/kg intravenously every 2 weeks and Dasatinib 60 mg/m2/dose (max 100 mg) oral once daily (DL1)
Study: 37398992
Drug: Ganitumab 18
Normalized name: Ganitumab
DrugBank: Ganitumab (DB12205)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ganitumab 18 mg/kg intravenously every 2 weeks and Dasatinib 60 mg/m2/dose (max 70 mg) twice daily (DL2)
Study: 37398992
Drug: Ganitumab 18
Normalized name: Ganitumab
DrugBank: Ganitumab (DB12205)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ganitumab 18 mg/kg every 2 weeks and Dasatinib 60 mg/m2/dose daily
Study: 37399456
Drug: Defibrotide (6.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Defibrotide (6.25 mg/kg)
Study: 37399757
Drug: D-cycloserine (DCS)
Normalized name: D-Cycloserine
DrugBank: Cycloserine (DB00260)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: D-cycloserine (DCS) augmentation of exposure-based CBT
Study: 37399757
Drug: Exposure-based CBT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure-based CBT without DCS augmentation
Study: 37400353
Drug: Bacillus Calmette-Guérin
Normalized name: Bacillus Calmette-Guérin (BCG) vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bacillus Calmette-Guérin (BCG) therapy
Study: 37400432
Drug: Stanford Neuromodulation
Normalized name: Stangard
DrugBank: Stannous fluoride (DB11092)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Stanford Neuromodulation Therapy (SNT)
Study: 37400758
Drug: Pharmacist-led deprescribing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist-led deprescribing intervention (education of health care personnel, access to standardized discontinuation regimens, patient education, support of transitional care)
Study: 37400806
Drug: Circulating DNA
Normalized name: Toxoplasma gondii DNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Circulating DNA (cDNA) detection before potentiated radiotherapy and at 3 months post-treatment.
Study: 37400812
Drug: Saccharomyces boulardii
Normalized name: Saccharomyces boulardii
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saccharomyces boulardii (Sb) 600 mg orally once daily for eight days
Study: 37400844
Drug: FCN-159 8
Approvals — FDA: no, EMA: no, PMDA: no
Description: FCN-159 8 mg
Study: 37400844
Drug: FCN-159 12
Approvals — FDA: no, EMA: no, PMDA: no
Description: FCN-159 12 mg
Study: 37400844
Drug: FCN-159 (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: FCN-159 (all doses)
Study: 37400849
Drug: Resin infiltration
Normalized name: Benzoin resin
DrugBank: Benzoin resin (DB11222)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resin infiltration treatment (Icon®) applied to hypomineralised enamel lesions
Study: 37400849
Drug: Resin infiltration
Normalized name: Benzoin resin
DrugBank: Benzoin resin (DB11222)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resin infiltration treatment (Icon®)
Study: 37401618
Drug: MPV-4 (quadrivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: MPV-4 (quadrivalent meningococcal polysaccharide vaccine)
Study: 37401618
Drug: MCV-4 (quadrivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: MCV-4 (quadrivalent meningococcal conjugate vaccine, Menactra®)
Study: 37401774
Drug: SARS-CoV-2 antibodies
Approvals — FDA: no, EMA: no, PMDA: no
Description: SARS-CoV-2 antibodies
Study: 37401993
Drug: Co-encapsulated antiretrovirals
Normalized name: poly (lactide-co-glycolide)-polyethylene glycol nanoparticles encapsulating quercetin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-encapsulated antiretrovirals (ARVs) with ingestible sensor (IS) pills from baseline through week 16.
Study: 37402024
Drug: Nasal esketamine
Normalized name: esketamine Nasal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal esketamine (56 mg) after pretreatment with nasal oxymetazoline (0.05%)
Study: 37402024
Drug: Nasal esketamine
Normalized name: esketamine Nasal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal esketamine (56 mg) after 16 consecutive days of mometasone (200 µg)
Study: 37402024
Drug: Nasal esketamine
Normalized name: esketamine Nasal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal esketamine (56 mg)
Study: 37402144
Drug: THRIVE intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: THRIVE intervention (cognitive behavioral app used daily over 21 days with weekly telephone coaching)
Study: 37402153
Drug: ViTT vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ViTT vaccine
Study: 37402153
Drug: ViPS vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ViPS vaccine
Study: 37402153
Drug: Control meningococcal
Normalized name: MENINGOCOCCAL B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control meningococcal vaccine
Study: 37402281
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for vulvovaginal discomfort
Study: 37402471
Drug: Dual oral
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual oral metronomic vinorelbine and capecitabine (mNC) regimen: oral vinorelbine (VNR) 40 mg three times weekly and capecitabine (CAP) 500 mg three times a day
Study: 37402471
Drug: Dual oral
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual oral metronomic vinorelbine and capecitabine (mNC) regimen
Study: 37402852
Drug: Treatments improving
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatments improving anhedonia and normalizing brain reward function
Study: 37402864
Drug: Methadone-exposed children
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone-exposed children with pharmacological treatment for NAS/NOWS (n=47)
Study: 37402864
Drug: Methadone-exposed children
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone-exposed children without pharmacological treatment for NAS/NOWS (n=51)
Study: 37403057
Drug: MAPS+ (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAPS+ (6 proactive MAPS-based counseling calls over 12 months plus a 24-month digital treatment adjuvant)
Study: 37403159
Drug: Low-dose risperidone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose risperidone in combination with sertraline (RS group)
Study: 37403159
Drug: Regular-dose risperidone
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Regular-dose risperidone (control group)
Study: 37404205
Drug: Faster Insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Faster Insulin Aspart
Study: 37404205
Drug: Standard Insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Insulin Aspart
Study: 37404855
Drug: High-dose n-3
Normalized name: 22:6(n-3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose n-3 (EPA + DHA) supplementation
Study: 37404855
Drug: High-dose n-6
Normalized name: 18:3 (n-6)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose n-6 (LA) supplementation
Study: 37405334
Drug: Vasodilator drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vasodilator drugs
Study: 37405504
Drug: Qualitative CT
Normalized name: CT-179
DrugBank: CT-179 (DB17114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qualitative CT scan analyses with simple clinical and biological parameters
Study: 37405662
Drug: Anti-infective therapy
Normalized name: gentian violet
DrugBank: Gentian violet cation (DB00406)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anti-infective therapy along with a mixture of allografts with or without a collagen barrier membrane
Study: 37405785
Drug: Fucoxanthin 12
Normalized name: Fucoxanthin
DrugBank: Fucoxanthin (DB15462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fucoxanthin 12 mg once a day for 12 weeks
Study: 37406106
Drug: Pembrolizumab, trastuzumab,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab, trastuzumab, and chemotherapy (PTC)
Study: 37406251
Drug: Daily GH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily GH (0.034 mg/kg/d)
Study: 37406769
Drug: High 1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: High 1000 mg daily prenatal DHA supplement
Study: 37406769
Drug: Low 200
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low 200 mg daily prenatal DHA supplement
Study: 37406777
Drug: Booster dose
Normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Booster dose of VLA2001
Study: 37406777
Drug: Booster dose
Normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Booster dose of VLA2001 in VLA2001-primed participants
Study: 37406777
Drug: Booster dose
Normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Booster dose of VLA2001 in ChAdOx1-S-primed participants
Study: 37407040
Drug: Calcium Soft
Normalized name: CVS Calcium Soft Chew (Caramel)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium Soft Chew D3 and a multivitamin supplement (MVS) specifically developed according to the type of operation; oesophagectomy group receives Multi-E, gastrectomy group receives Multi-G. MVSs taken once daily, Calcium Soft Chew D3 two times per day.
Study: 37407059
Drug: Global School-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Global School-based Student Health Survey (GSHS) administered to students.
Study: 37407096
Drug: Digital cognitive
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital cognitive behavioural therapy for insomnia (n=48)
Study: 37407142
Drug: Dasatinib plus
Normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Dasatinib plus EsPhALL chemotherapy
Study: 37407142
Drug: Imatinib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib plus chemotherapy
Study: 37407326
Drug: CYP2D6 genotype-guided
Normalized name: PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 8
DrugBank: Streptococcus pneumoniae type 8 capsular polysaccharide antigen (DB10326)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CYP2D6 genotype-guided metoprolol administration
Study: 37814224
Drug: Goal-directed hemodynamic
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goal-directed hemodynamic therapy (GDHT)
Study: 37408075
Drug: Cefepime/zidebactam (WCK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefepime/zidebactam (WCK 5222) administered under compassionate use
Study: 37408075
Drug: Polymyxins (failed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polymyxins (failed treatment)
Study: 37409159
Drug: GH001 (5-methoxy-N,N-dimethyltryptamine)
Normalized name: 5-methoxy-N-acetyltryptamine
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: GH001 (5-methoxy-N,N-dimethyltryptamine) 12 mg
Study: 37409159
Drug: GH001 (5-methoxy-N,N-dimethyltryptamine)
Normalized name: 5-methoxy-N-acetyltryptamine
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: GH001 (5-methoxy-N,N-dimethyltryptamine) 18 mg
Study: 37409159
Drug: GH001 (5-methoxy-N,N-dimethyltryptamine)
Normalized name: 5-methoxy-N-acetyltryptamine
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: GH001 (5-methoxy-N,N-dimethyltryptamine) individualized dosing
Study: 37409229
Drug: Ladarixin (LDX)
Normalized name: Ladarixin
DrugBank: Ladarixin (DB16212)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ladarixin (LDX) 400 mg twice daily for three cycles of 14 days on/14 days off
Study: 37409757
Drug: Betaine supplementation
Normalized name: betaine
DrugBank: Betaine (DB06756)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betaine supplementation (2.5 and 5.0 g/d)
Study: 37409992
Drug: Adjunctive Transcoronary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive Transcoronary Pacing Strategy
Study: 37410050
Drug: Calcipotriene-Betamethasone Dipropionate
Normalized name: Betamethasone Dipropionate/Calcipotriene 0.064%-0.005% Topical application Ointment [CALCIPOTRIENE-BETAMETHASONE DIPROPIONATE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriene-Betamethasone Dipropionate (CAL/BDP) cream
Study: 37410050
Drug: Calcipotriene-Betamethasone Dipropionate
Normalized name: Betamethasone Dipropionate/Calcipotriene 0.064%-0.005% Topical application Ointment [CALCIPOTRIENE-BETAMETHASONE DIPROPIONATE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriene-Betamethasone Dipropionate (CAL/BDP) topical solution
Study: 37410421
Drug: Low-dose mindfulness
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose mindfulness comparator (LDC)
Study: 37410465
Drug: Risk-stratified care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risk-stratified care (physiotherapy treatment tailored for risk category)
Study: 37410740
Drug: Medication purchased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication purchased in the informal sector
Study: 37410740
Drug: Medication purchased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication purchased in the formal sector
Study: 37410740
Drug: Antibiotic usage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic usage in the informal sector
Study: 37413896
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (TAU) (n = 41)
Study: 37414060
Drug: ARI0002h (BCMA-directed
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARI0002h (BCMA-directed CAR T-cell therapy)
Study: 37414066
Drug: Cabamiquine 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabamiquine 60 mg
Study: 37414066
Drug: Cabamiquine 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabamiquine 80 mg
Study: 37414066
Drug: Cabamiquine 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabamiquine 100 mg
Study: 37414066
Drug: Cabamiquine 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabamiquine 200 mg
Study: 37414066
Drug: Cabamiquine 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabamiquine 30 mg
Study: 37414066
Drug: Cabamiquine 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabamiquine 30 mg, 60 mg, 80 mg
Study: 37414066
Drug: Cabamiquine (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabamiquine (all doses)
Study: 37414137
Drug: Tumor necrosis
Normalized name: Tumor necrosis factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tumor necrosis factor inhibitor (TNFi)
Study: 37414215
Drug: Neoadjuvant pembrolizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant pembrolizumab 200 mg IV followed by 1 year of adjuvant pembrolizumab
Study: 37414460
Drug: PAXI (Patient
Approvals — FDA: no, EMA: no, PMDA: no
Description: PAXI (Patient advice plus exercise plus corticosteroid injection)
Study: 37414702
Drug: Positron emission
Normalized name: propofol lipid emulsion Injection [Propoven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positron emission tomography/computed tomography (PET/CT) with 296 MBq injection
Study: 37414705
Drug: Dose-dense methotrexate-vinblastine-adriamycin-cisplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-dense methotrexate-vinblastine-adriamycin-cisplatin (ddMVAC)
Study: 37414899
Drug: Fecal microbiota
Normalized name: Fecal Microbiota
DrugBank: Fecal microbiota (DB17743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fecal microbiota transplantation (FMT) plus PD-1 inhibitors (nivolumab or pembrolizumab)
Study: 37414899
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (FMT plus PD-1 inhibitors)
Study: 37414923
Drug: Tenofovir-based antiretroviral
Normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tenofovir-based antiretroviral therapy (tenofovir, lamivudine, efavirenz)
Study: 37415100
Drug: Surgery (11
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgery (11 as primary treatment and 4 during follow-up)
Study: 37415100
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin injection or platelet rich plasma injection
Study: 37415239
Drug: DZD1516 monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DZD1516 monotherapy at 250 mg, twice daily (BID)
Study: 37415239
Drug: DZD1516 monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DZD1516 monotherapy
Study: 37415246
Drug: Adjunctive lifestyle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive lifestyle intervention
Study: 37415648
Drug: Combined Therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined Therapy (CT) - oral dutasteride 0.5 mg/tamsulosin hydrochloride 0.4 mg per day
Study: 37415712
Drug: Traditional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional therapy (cognitive stimulation and occupational activities)
Study: 37415845
Drug: Camrelizumab 200
Normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Camrelizumab 200 mg every 3 weeks and famitinib 20 mg once per day
Study: 37417239
Drug: Endovascular therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular therapy (EVT) after 1 pass
Study: 37417239
Drug: Endovascular therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular therapy (EVT) after 2 passes
Study: 37417239
Drug: Endovascular therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular therapy (EVT) after 3 to 7 passes
Study: 37417239
Drug: Endovascular therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular therapy (EVT) with failed reperfusion
Study: 37417619
Drug: Dialyzable leukocyte
Normalized name: Dialyzable leukocyte extract
DrugBank: Dialyzable leukocyte extract (DB16530)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialyzable leukocyte extract (DLE) administered orally at 2 mg per day for 5 days, followed by 4 mg per week for 5 weeks, and then 2 mg per week for 5 weeks.